Register to View Atopic Dermatitis Disease Activity and Initiation of Systemic Therapy in the Real-World Setting

On May 15 – May 18, 2022, this poster was on display at ISPOR 2022.

What is the Objective of this Poster?

• The BSA x PGA product shows promise as a single metric to measure DA in
  AD patients given the ability to predict STI.
• Given the complexity of collecting clinical trial outcome measures in AD
  patients during routine clinical practice, the BSA x PGA product appears to
  be a pragmatic solution in generating real-world evidence for AD.